125 related articles for article (PubMed ID: 38359367)
1. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis.
Kleinstern G; Boddicker NJ; O'Brien DR; Allmer C; Rabe KG; Norman AD; Griffin R; Yan H; Ma T; Call TG; Bruins L; Brown S; Bonolo de Campos C; Hanson CA; Leis JF; Ding W; Vachon CM; Kay NE; Oakes CC; Parker AS; Brander DM; Weinberg JB; Furman RR; Shanafelt TD; Cerhan JR; Parikh SA; Braggio E; Slager SL
Blood Adv; 2024 May; 8(9):2118-2129. PubMed ID: 38359367
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.
Kleinstern G; O'Brien DR; Li X; Tian S; Kabat BF; Rabe KG; Norman AD; Yan H; Vachon CM; Boddicker NJ; Call TG; Parikh SA; Bruins L; Bonolo de Campos C; Leis JF; Shanafelt TD; Ding W; Cerhan JR; Kay NE; Slager SL; Braggio E
Am J Hematol; 2020 Aug; 95(8):906-917. PubMed ID: 32279347
[TBL] [Abstract][Full Text] [Related]
3. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
4. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
[TBL] [Abstract][Full Text] [Related]
5. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
Parikh SA; Rabe KG; Kay NE; Call TG; Ding W; Leis JF; Kenderian SS; Muchtar E; Wang Y; Koehler AB; Schwager SM; Lesnick CE; Kleinstern G; Van Dyke D; Hanson CA; Braggio E; Slager SL; Shanafelt TD
Blood; 2021 Jul; 138(2):149-159. PubMed ID: 33876228
[TBL] [Abstract][Full Text] [Related]
6. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.
Barrio S; Shanafelt TD; Ojha J; Chaffee KG; Secreto C; Kortüm KM; Pathangey S; Van-Dyke DL; Slager SL; Fonseca R; Kay NE; Braggio E
Leukemia; 2017 Jan; 31(1):170-176. PubMed ID: 27469216
[TBL] [Abstract][Full Text] [Related]
7. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring.
Dagklis A; Fazi C; Sala C; Cantarelli V; Scielzo C; Massacane R; Toniolo D; Caligaris-Cappio F; Stamatopoulos K; Ghia P
Blood; 2009 Jul; 114(1):26-32. PubMed ID: 19029437
[TBL] [Abstract][Full Text] [Related]
8. Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
Balakrishna J; Basumallik N; Matulonis R; Scott D; Salem D; Jasper G; Wiestner A; Stetler-Stevenson M; Marti G; Sun C; Yuan CM
Leuk Lymphoma; 2021 Aug; 62(8):1828-1839. PubMed ID: 33734005
[TBL] [Abstract][Full Text] [Related]
9. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
10. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.
Shanafelt TD; Kay NE; Jenkins G; Call TG; Zent CS; Jelinek DF; Morice WG; Boysen J; Zakko L; Schwager S; Slager SL; Hanson CA
Blood; 2009 Apr; 113(18):4188-96. PubMed ID: 19015397
[TBL] [Abstract][Full Text] [Related]
11. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.
Call TG; Norman AD; Hanson CA; Achenbach SJ; Kay NE; Zent CS; Ding W; Cerhan JR; Rabe KG; Vachon CM; Hallberg EJ; Shanafelt TD; Slager SL
Cancer; 2014 Jul; 120(13):2000-5. PubMed ID: 24711224
[TBL] [Abstract][Full Text] [Related]
12. A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).
Molica S; Giannarelli D; Levato L; Mirabelli R; Gentile M; Lentini M; Morabito F
Int J Hematol; 2014 Sep; 100(3):290-5. PubMed ID: 25064370
[TBL] [Abstract][Full Text] [Related]
13. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia.
Henriques A; Rodríguez-Caballero A; Nieto WG; Langerak AW; Criado I; Lécrevisse Q; González M; Pais ML; Paiva A; Almeida J; Orfao A
PLoS One; 2013; 8(7):e67751. PubMed ID: 23844084
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?
Angelillo P; Capasso A; Ghia P; Scarfò L
Eur J Intern Med; 2018 Dec; 58():2-6. PubMed ID: 30268574
[TBL] [Abstract][Full Text] [Related]
15. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Brieghel C; da Cunha-Bang C; Yde CW; Schmidt AY; Kinalis S; Nadeu F; Andersen MA; Jacobsen LO; Andersen MK; Pedersen LB; Delgado J; Baumann T; Mattsson M; Mansouri L; Rosenquist R; Campo E; Nielsen FC; Niemann CU
Clin Cancer Res; 2020 Mar; 26(6):1507-1515. PubMed ID: 31919133
[TBL] [Abstract][Full Text] [Related]
16. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
Abdelbaky SB; Giacopelli B; Rabe KG; Yamaguchi K; Wu YZ; Yan H; Shanafelt TD; Parikh SA; Ding W; Hampel PJ; Brown S; Cerhan JR; Vachon CM; Kay NE; Hanson CA; Parker AS; Braggio E; Slager SL; Oakes CC
Blood; 2024 Apr; 143(17):1752-1757. PubMed ID: 38194687
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
Rawstron AC; Bennett FL; O'Connor SJ; Kwok M; Fenton JA; Plummer M; de Tute R; Owen RG; Richards SJ; Jack AS; Hillmen P
N Engl J Med; 2008 Aug; 359(6):575-83. PubMed ID: 18687638
[TBL] [Abstract][Full Text] [Related]
18. What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges.
Scarfò L; Ghia P
Semin Oncol; 2016 Apr; 43(2):201-8. PubMed ID: 27040697
[TBL] [Abstract][Full Text] [Related]
19. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.
Fazi C; Scarfò L; Pecciarini L; Cottini F; Dagklis A; Janus A; Talarico A; Scielzo C; Sala C; Toniolo D; Caligaris-Cappio F; Ghia P
Blood; 2011 Dec; 118(25):6618-25. PubMed ID: 21876118
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.
Molica S; Mauro FR; Molica M; Del Giudice I; Foà R
Leuk Lymphoma; 2012 Sep; 53(9):1660-5. PubMed ID: 22335530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
